Altrius Capital Management Inc Grows Stake in GSK plc (NYSE:GSK)

Altrius Capital Management Inc lifted its holdings in shares of GSK plc (NYSE:GSK) by 8.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 216,000 shares of the pharmaceutical company’s stock after acquiring an additional 17,578 shares during the quarter. GSK makes up 2.0% of Altrius Capital Management Inc’s portfolio, making the stock its 13th biggest position. Altrius Capital Management Inc’s holdings in GSK were worth $7,305,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. FMR LLC increased its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its position in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares during the period. Clifford Capital Partners LLC raised its stake in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after buying an additional 51,378 shares in the last quarter. Cerity Partners LLC lifted its holdings in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after buying an additional 165,556 shares during the period. Finally, Natixis Advisors LLC boosted its position in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.2 %

NYSE:GSK opened at $37.33 on Friday. The firm has a 50-day simple moving average of $34.91 and a two-hundred day simple moving average of $37.30. The firm has a market cap of $77.36 billion, a P/E ratio of 23.47, a P/E/G ratio of 1.12 and a beta of 0.64. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.21%. GSK’s dividend payout ratio (DPR) is 98.74%.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of research analyst reports. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.